Anika Therapeutics, Inc. (ANIK)
| Market Cap | 200.91M |
| Revenue (ttm) | 116.26M |
| Net Income (ttm) | -11.06M |
| Shares Out | 13.31M |
| EPS (ttm) | -0.78 |
| PE Ratio | n/a |
| Forward PE | 65.65 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 166,370 |
| Open | 14.58 |
| Previous Close | 14.62 |
| Day's Range | 14.58 - 15.16 |
| 52-Week Range | 7.87 - 16.24 |
| Beta | 0.23 |
| Analysts | Buy |
| Price Target | 17.50 (+15.89%) |
| Earnings Date | Jul 29, 2026 |
About ANIK
Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and ... [Read more]
Financial Performance
In 2025, Anika Therapeutics's revenue was $112.82 million, a decrease of -5.91% compared to the previous year's $119.91 million. Losses were -$10.88 million, -80.70% less than in 2024.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for ANIK stock is "Buy." The 12-month stock price target is $17.5, which is an increase of 15.89% from the latest price.
News
Anika Therapeutics Transcript: AGM 2026
The meeting covered board introductions, five key proposals, and voting procedures. All proposals, including director elections, auditor ratification, executive compensation, and plan amendments, passed by majority vote. No questions were submitted by stockholders.
Anika Therapeutics Proxy statement: Proxy filing
Anika Therapeutics filed a proxy statement on June 8, 2026, providing details for shareholder voting and corporate governance matters.
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early inte...
Anika Therapeutics Proxy statement: Proxy filing
Anika Therapeutics filed a proxy statement on June 1, 2026, providing details for shareholder voting and corporate governance matters.
Anika Therapeutics reports Q1 EPS 27c vs.(6c) last year
Reports Q1 revenue $29.6M vs. $26.2M last year. Reports total company revenue grew 13%, driven by commercial channel strength and favorable OEM channel order timing. “Our strategic transformation and ...
Anika Therapeutics Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 13% year-over-year to $29.6 million, driven by strong commercial and OEM channels, improved gross margin, and accelerating Integrity adoption. Full-year guidance is maintained, with continued investment in innovation and operational efficiency.
Anika Therapeutics Earnings release: Q1 2026
Anika Therapeutics released its Q1 2026 earnings on April 29, 2026, summarizing the period's financial results.
Anika Therapeutics Slides: Q1 2026
Anika Therapeutics has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 29, 2026.
Anika Therapeutics Quarterly report: Q1 2026
Anika Therapeutics has published its Q1 2026 quarterly earnings report on April 29, 2026.
Anika Reports First Quarter 2026 Financial Results
Grew total company revenue 13%, driven by Commercial Channel strength and favorable OEM Channel order timing Delivered 64% gross margin, +8 points year over year, driven by improved operational execut...
Anika Therapeutics Proxy statement: Proxy filing
Anika Therapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Anika Therapeutics Proxy statement: Proxy filing
Anika Therapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Anika to Issue First Quarter 2026 Financial Results on Wednesday, April 29, 2026
BEDFORD, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue it...
Anika Therapeutics Transcript: 2026 CG Musculoskeletal Conference
The conference highlighted a robust hyaluronic acid-based product portfolio, strong commercial growth, and a focus on expanding regenerative solutions. Regulatory progress for Hyalofast and Cingal, along with disciplined R&D and operational improvements, support a positive outlook.
Anika Therapeutics Slides: FY 2026
Anika Therapeutics has posted slides in relation to its FY 2026 quarterly earnings report, which was published on March 2, 2026.
Anika Therapeutics price target raised to $17 from $16 at Barrington
Barrington analyst Michael Petusky raised the firm’s price target on Anika Therapeutics (ANIK) to $17 from $16 and keeps an Outperform rating on the shares. The company reported a Q4…
Anika Therapeutics price target raised to $18 from $16 at B. Riley
B. Riley raised the firm’s price target on Anika Therapeutics (ANIK) to $18 from $16 and keeps a Buy rating on the shares. Anika Therapeutics reported strong Q4 results, with…
Anika Therapeutics Earnings Call Transcript: Q4 2025
Commercial channel revenue grew strongly in 2025, offsetting OEM declines from U.S. pricing pressures. 2026 guidance projects 1–9% revenue growth, with commercial channel expected to rise 10–20% and continued investment in innovation and operational efficiency.
Anika Therapeutics Annual report: Q4 2025
Anika Therapeutics has published its Q4 2025 annual report on February 26, 2026.
Anika Therapeutics Earnings release: Q4 2025
Anika Therapeutics released its Q4 2025 earnings on February 26, 2026, summarizing the period's financial results.
Anika Therapeutics Slides: Q4 2025
Anika Therapeutics has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 26, 2026.
Anika Therapeutics reports Q4 EPS 31c vs (3c) last year
Reports Q4 revenue $30.6M vs $30.6M last year. “We closed 2025 with a strong fourth quarter, with top-line growth led by our Commercial Channel and company-wide results that included expanded…
Anika Therapeutics sees FY26 revenue $114M-$122.5M
Anika is providing the following 2026 guidance: Total Company Revenue between $114 and $122.5 million, up 1% to 9% year over year; Commercial Channel, $53 to $58 million, maintaining up…
Anika Reports Fourth Quarter and Full Year 2025 Financial Results
Met 2025 revenue and exceeded revised adjusted EBITDA; reaffirms 2026 revenue and sets adjusted EBITDA target Commercial Channel grew 22% and 15% for Q4 and full year, respectively Generated $11.2 mil...
Anika To Present at the Canaccord Genuity 2026 Musculoskeletal Conference
BEDFORD, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Steve Griffin, Pr...